Overactive bladder
Conditions
Interventions
Imidafenacin 0.1mg will be orally administered twice a day, once after breakfast and dinner for 12 weeks.
Solifenacin 5mg will be orally administered once after breakfast for 12 weeks.
Sponsors
Clinical Research Support Center Kyushu
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) OAB patients (urgency score (OABSS) >= 2 and nighttime frequency score >= 2) 2) 20 years old or more patients 3) Patients from whom we have received written consent.
Exclusion criteria
Exclusion criteria: 1) Patients who have administered prohibited substances or done prohibited therapy within the 4weeks before enrollment 2) Patients who started restricted substances and changed usage or dosage of restricted substances for determined period before enrollment 3) Patients with prostate cancer, neurogenic bladder, urethral stricture, chronic bacterial prostatitis, urinary tract infection, urinary tract stones and interstitial cystitis 4) Patients with urinary retention 5) Patients with obstruction of pylorus, duodenum and gut and patients with paralytic ileus 6) Patients with decrease of enterokinesis and gastrointestinal tract tension 7) Patients with closure-angle glaucoma 8) Patients with myasthenia gravis 9) Patients with serious liver dysfunction, kidney dysfunction and heart disease. 10) Hypersensitivity to anti-cholinergic agents. 11) Residual urine volume is more than 100mL 12) Patients with polyuria 13) Any other patients who are regarded as unsuitable for this study by the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Usefulness for nocturia | — |
Countries
Japan
Contacts
Public ContactSadaaki Sakamoto
Nakamura Hospital Urology
Outcome results
None listed